目的总结胰高血糖素样肽-1(GLP-1)类似物的研发进展。方法检索PubMed和Web of Science数据库自建库起至2024年2月20日的GLP-1类似物相关文献,从研发概况、单分子多靶点GLP-1受体激动剂(GLP-1RA)、除治疗糖尿病外的其他适应证及其药物研...目的总结胰高血糖素样肽-1(GLP-1)类似物的研发进展。方法检索PubMed和Web of Science数据库自建库起至2024年2月20日的GLP-1类似物相关文献,从研发概况、单分子多靶点GLP-1受体激动剂(GLP-1RA)、除治疗糖尿病外的其他适应证及其药物研发新趋势方面,总结GLP-1类似物的研发进展。结果与结论GLP-1类似物的研发经历了从短效到长效,从注射剂到口服剂,并扩展到多靶点治疗的过程。目前,多靶点GLP-1RA包括GLP-1R/葡萄糖依赖性促胰岛素释放多肽受体、GLP-1R/胰高血糖素受体(GCGR)、GLP-1R/GLP-2R、GLP-1R/胰淀素3受体(AMY3R)、GLP-1R/成纤维细胞生长因子21受体(FGF-21R)等双靶点激动剂,以及GLPR/GLP-1R/GCGR、GLP-1R/GCGR/FGF-21R等三靶点激动剂。GLP-1类似物展现了在2型糖尿病、超重、肥胖症、心血管疾病、多囊卵巢综合征、非酒精性脂肪性肝炎、慢性肾脏病等疾病治疗的巨大潜力,疗效优于单靶点的双靶点和三靶点GLP-1RA是近年来研发的重点。GLP-1类似物的重组腺相关病毒载体基因治疗为研发新趋势,其现阶段存在的安全性、依从性等问题和可供参考的解决方法也一并被提出。展开更多
目的用马来酰亚胺活化的相对分子质量40000的聚乙二醇(MAL-PEG40K)定点修饰胰高血糖素样肽-1衍生物(glucagon like peptide-1analogue,GLP-1a),并分析修饰产物部分性质。方法采用MAL-PEG40K定点修饰GLP-1a,强阳离子交换层析分离纯化修...目的用马来酰亚胺活化的相对分子质量40000的聚乙二醇(MAL-PEG40K)定点修饰胰高血糖素样肽-1衍生物(glucagon like peptide-1analogue,GLP-1a),并分析修饰产物部分性质。方法采用MAL-PEG40K定点修饰GLP-1a,强阳离子交换层析分离纯化修饰混合物,SDS-PAGE及反相高压液相色谱法(RP-HPLC)检测修饰产物MAL-PEG40KGLP-1a纯度,报告基因法检测其体外活性,动物急性降血糖试验检测其体内生物学活性。结果MAL-PEG40K-GLP-1a经SDS-PAGE及RP-HPLC分析,纯度分别为95%和98.1%,体外活性保留率为22.9%,体内具有显著降血糖作用且药效时间明显延长。结论制备的MAL-PEG40K-GLP-1a药学性质获得显著改善,有望开发为安全、长效的新型GLP-1受体激动剂。展开更多
Incretin-based therapies have revolutionized the medical management of type 2 diabetes mellitus(T2DM) in the 21 st century. Glucagon-like peptide-1(GLP-1) suppresses appetite and gastric motility, and has trophic effe...Incretin-based therapies have revolutionized the medical management of type 2 diabetes mellitus(T2DM) in the 21 st century. Glucagon-like peptide-1(GLP-1) suppresses appetite and gastric motility, and has trophic effects on pancreas, cardio-protective and renal effects. GLP-1 analogues and dipeptidyl peptidase-4 inhibitors form the incretin-based therapies. Significant reduction of hemoglobin A1 c when used as monotherapy and in combination regimens, favorable effects on body weight, and low risk of hypoglycemia are their unique therapeutic benefits. Their safety and tolerability are comparable to other anti-diabetic medications. Concern about elevated risk of pancreatitis has been discarded by two recent meta-analyses. This article discusses the therapeutic manipulation of incretin system for the management of T2 DM.展开更多
文摘目的总结胰高血糖素样肽-1(GLP-1)类似物的研发进展。方法检索PubMed和Web of Science数据库自建库起至2024年2月20日的GLP-1类似物相关文献,从研发概况、单分子多靶点GLP-1受体激动剂(GLP-1RA)、除治疗糖尿病外的其他适应证及其药物研发新趋势方面,总结GLP-1类似物的研发进展。结果与结论GLP-1类似物的研发经历了从短效到长效,从注射剂到口服剂,并扩展到多靶点治疗的过程。目前,多靶点GLP-1RA包括GLP-1R/葡萄糖依赖性促胰岛素释放多肽受体、GLP-1R/胰高血糖素受体(GCGR)、GLP-1R/GLP-2R、GLP-1R/胰淀素3受体(AMY3R)、GLP-1R/成纤维细胞生长因子21受体(FGF-21R)等双靶点激动剂,以及GLPR/GLP-1R/GCGR、GLP-1R/GCGR/FGF-21R等三靶点激动剂。GLP-1类似物展现了在2型糖尿病、超重、肥胖症、心血管疾病、多囊卵巢综合征、非酒精性脂肪性肝炎、慢性肾脏病等疾病治疗的巨大潜力,疗效优于单靶点的双靶点和三靶点GLP-1RA是近年来研发的重点。GLP-1类似物的重组腺相关病毒载体基因治疗为研发新趋势,其现阶段存在的安全性、依从性等问题和可供参考的解决方法也一并被提出。
文摘目的用马来酰亚胺活化的相对分子质量40000的聚乙二醇(MAL-PEG40K)定点修饰胰高血糖素样肽-1衍生物(glucagon like peptide-1analogue,GLP-1a),并分析修饰产物部分性质。方法采用MAL-PEG40K定点修饰GLP-1a,强阳离子交换层析分离纯化修饰混合物,SDS-PAGE及反相高压液相色谱法(RP-HPLC)检测修饰产物MAL-PEG40KGLP-1a纯度,报告基因法检测其体外活性,动物急性降血糖试验检测其体内生物学活性。结果MAL-PEG40K-GLP-1a经SDS-PAGE及RP-HPLC分析,纯度分别为95%和98.1%,体外活性保留率为22.9%,体内具有显著降血糖作用且药效时间明显延长。结论制备的MAL-PEG40K-GLP-1a药学性质获得显著改善,有望开发为安全、长效的新型GLP-1受体激动剂。
文摘Incretin-based therapies have revolutionized the medical management of type 2 diabetes mellitus(T2DM) in the 21 st century. Glucagon-like peptide-1(GLP-1) suppresses appetite and gastric motility, and has trophic effects on pancreas, cardio-protective and renal effects. GLP-1 analogues and dipeptidyl peptidase-4 inhibitors form the incretin-based therapies. Significant reduction of hemoglobin A1 c when used as monotherapy and in combination regimens, favorable effects on body weight, and low risk of hypoglycemia are their unique therapeutic benefits. Their safety and tolerability are comparable to other anti-diabetic medications. Concern about elevated risk of pancreatitis has been discarded by two recent meta-analyses. This article discusses the therapeutic manipulation of incretin system for the management of T2 DM.
